Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Ravandi, Farhad  [Clear All Filters]
2015
Oran, B., Jimenez, A.M., de Lima, M., Popat, U.R., Bassett, R., Andersson, B., Borthakur, G., Bashir, Q., Chen, J., Ciurea, S.O., et al. (2015). Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation.Biol Blood Marrow Transplant.
Takahashi, K., Kantarjian, H., Garcia-Manero, G., Borthakur, G., Kadia, T., DiNardo, C., Jabbour, E., Pierce, S., Estrov, Z., Konopleva, M., et al. (2015). Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients.Clin Lymphoma Myeloma Leuk.
Daver, N., Thomas, D., Ravandi, F., Cortes, J., Garris, R., Jabbour, E., Garcia-Manero, G., Borthakur, G., Kadia, T., Rytting, M., et al. (2015). Final report of a phase II study of imatinib mesylate with hyper-CVAD for the frontline treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia.Haematologica.
Ravandi, F., Jorgensen, J.L., O'Brien, S.M., Jabbour, E., Thomas, D.A., Borthakur, G., Garris, R., Huang, X., Garcia-Manero, G., Burger, J.A., et al. (2015). Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia.Br J Haematol.
Sasaki, K., Strom, S.S., O'Brien, S., Jabbour, E., Ravandi, F., Konopleva, M., Borthakur, G., Pemmaraju, N., Daver, N., Jain, P., et al. (2015). Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials.Lancet Haematol2, e186-93.
2013
Ravandi, F., Jorgensen, J.L., Thomas, D.A., O'Brien, S., Garris, R., Faderl, S., Huang, X., Wen, S., Burger, J.A., Ferrajoli, A., et al. (2013). Detection of MRD may predict the outcome of patients with Philadelphia-chromosome positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.Blood.
Strati, P., Kantarjian, H., Thomas, D., O'Brien, S., Konoplev, S., Jorgensen, J.L., Luthra, R., Abruzzo, L., Jabbour, E., Quintas-Cardama, A., et al. (2013). HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia.Cancer.
Raza, A., Ravandi, F., Rastogi, A., Bubis, J., Lim, S.H., Weitz, I., Castro-Malaspina, H., Galili, N., Jawde, R.Abou, and Illingworth, A. (2013). A prospective multicenter study of paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure.Cytometry B Clin Cytom.
Raza, A., Ravandi, F., Rastogi, A., Bubis, J., Lim, S.H., Weitz, I., Castro-Malaspina, H., Galili, N., Jawde, R.Abou, and Illingworth, A. (2013). A Prospective Multicenter Study of Paroxysmal Nocturnal Hemoglobinuria Cells in Patients with Bone Marrow Failure.Cytometry B Clin Cytom.
Kornblau, S.M., Qutub, A., Yao, H., York, H., Qiu, Y.Hua, Graber, D., Ravandi, F., Cortes, J., Andreeff, M., Zhang, N., et al. (2013). Proteomic Profiling Identifies Distinct Protein Patterns in Acute Myelogenous Leukemia CD34+CD38- Stem-Like Cells.Plos One8, e78453.
Kantarjian, H., Thomas, D., Jorgensen, J., Kebriaei, P., Jabbour, E., Rytting, M., York, S., Ravandi, F., Garris, R., Kwari, M., et al. (2013). Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.Cancer.